Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway

Figure 5

Myr prevented NRCM hypertrophy in vitro. (a) Immunofluorescence (IF) staining of NRCM in different groups; (b) calculated cell surface area (>100 cells per group); (c–e) mRNA expression levels of ANP, BNP, and β-MHC, respectively; Nrf2 knockdown (f) and its downstream genes including HO-1 (g), NQQ-1 (h), and GCLC (i), respectively. All mRNA expressions of target genes were normalized to GAPDH; (j) DCF fluorescence was quantified to present the reactive oxygen species after different treatments indicated in the pictures; (k) representative western blots for SOD1, CAT, and 4-HEN after different treatments indicated in the pictures; (l) quantified SOD1, CAT1, and 4-HEN after normalized to GAPDH. Cellular experiments were repeated three times independently. versus the group indicated in the picture.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)